Zhu, C. Et Al. 2022. Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation. 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , (Amsterdam, Netherlands), 645-647.

Zhu, C., Kalincik, T., Horakova, D., Zhen, Z., Buzzard, K., Skibina, O., ... Alroughani, R.(2022). Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation . 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (pp.645-647). Amsterdam, Netherlands

Zhu, C. Et Al. "Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation," 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 2022

Zhu, C. Et Al. "Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation." 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , Amsterdam, Netherlands, pp.645-647, 2022

Zhu, C. Et Al. (2022) . "Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation." 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , Amsterdam, Netherlands, pp.645-647.

@conferencepaper{conferencepaper, author={C. Zhu Et Al. }, title={Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation}, congress name={38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis}, city={Amsterdam}, country={Netherlands}, year={2022}, pages={645-647} }